Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 495

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 495
---
.D.                    |     |    68 |     | Chief Executive Officer and Director |
| Dan Dearborn                          |     |    58 |     | Chief Financial Officer              |
| Non-Employee Directors                |     |       |     |                                      |
| James Manuso, Ph.D., MBA              |     |    76 |     | Director and Chairman of the Board   |
| Alan List, M.D.                       |     |    70 |     | Director                             |
| George Ng                             |     |    51 |     | Director                             |
| Robert E. Hoffman Craig Tendler, M.D. |     | 59 66 |     | Director Director                    |

Executive Officers James Bianco, M.D.has served as Legacy TuHURA’s Chief Executive Officer and as a director of Legacy TuHURA since July 1, 2021, and was appointed Chief Executive Officer of TuHURA and a director on the TuHURA Board of Directors following the completion of the Kintara Merger. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of Morphogenesis Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to TuHURA. Dr. Bianco is a 30-year veteran of the biopharmaceutical industry. In 1991, Dr. Bianco founded CTI Biopharma, Inc. (“CTI”) and from 1992 to 2016 was the Chief Executive Officer of CTI. During his tenure at CTI, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three receiving accelerated or conditional regulatory approval in the U.S. and/or E.U. Dr. Bianco earned his M.D. from the Mount Sinai Icahn School of Medicine and completed his residency and chief residency at the Mount Sinai Medical Center in New York City. He completed his fellowship in Hematology/Oncology at the University of Washington/Fred Hutchinson Cancer Research Center (FHCRC) where he was appointed Assistant Professor of Medicine, Assistant Member FHCRC and Director of the Bone Marrow Transplant Unit at a “Hutch” affiliate (SVAMC). TuHURA believes Dr. Bianco’s experience in building and leading biotechnology businesses as well as his